Scarica l'app Stockscreener
1.56
2.63%
0.04
Pre-mercato:
1.60
0.04
+2.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CABA Giù?
Forum
Previsione
Precedente Chiudi:
$1.52
Aprire:
$1.55
Volume 24 ore:
2.72M
Relative Volume:
1.60
Capitalizzazione di mercato:
$211.37M
Reddito:
-
Utile/perdita netta:
$-67.68M
Rapporto P/E:
-0.9398
EPS:
-1.66
Flusso di cassa netto:
$-54.24M
1 W Prestazione:
-11.86%
1M Prestazione:
-16.58%
6M Prestazione:
-31.28%
1 anno Prestazione:
-80.03%
Intervallo 1D:
$1.51
$1.615
Intervallo di 1 settimana:
$1.51
$1.82
Portata 52W:
$0.9857
$8.77
Cabaletta Bio Inc Stock (CABA) Company Profile
Nome
Cabaletta Bio Inc
Settore
Industria
Telefono
(267) 759-3100
Indirizzo
2929 ARCH STREET, PHILADELPHIA, PA
Confronta CABA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
1.56 | 211.37M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Iniziato | UBS | Buy |
| 2024-02-05 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Iniziato | William Blair | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Iniziato | Stifel | Buy |
| 2023-09-05 | Iniziato | Citigroup | Buy |
| 2023-07-18 | Iniziato | Guggenheim | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-01-08 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Iniziato | Cowen | Outperform |
| 2019-11-19 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Cabaletta Bio Inc Borsa (CABA) Ultime notizie
Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) PT at $20.33 - MarketBeat
Cabaletta Bio's SWOT analysis: CAR-T pioneer's stock faces market skepticism - Investing.com Australia
Cabaletta Bio’s SWOT analysis: CAR-T pioneer’s stock faces market skepticism - Investing.com Australia
Cabaletta Bio’s SWOT analysis: CAR-T pioneer’s stock faces market skepticism By Investing.com - Investing.com South Africa
Cantor Fitzgerald Weighs in on Cabaletta Bio FY2026 Earnings - MarketBeat
Cabaletta Bio's (CABA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cabaletta Bio Reports Promising Data from RESET Trials for Transformative Autoimmune Therapy - MSN
Cabaletta Bio stock price target reiterated on strong clinical data By Investing.com - Investing.com India
Cabaletta Bio stock price target reiterated on strong clinical data - Investing.com
Cabaletta Bio Prices Public Offering to Raise $100 Million - MSN
Cabaletta Bio Announces Public Offering of Common Stock and Warrants - MSN
H.C. Wainwright reiterates buy rating on Cabaletta Bio stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates buy rating on Cabaletta Bio stock - Investing.com Australia
Cabaletta Bio’s (CABA) Buy Rating Reaffirmed at HC Wainwright - Defense World
Analysts Offer Predictions for Cabaletta Bio FY2026 Earnings - Defense World
Cabaletta Bio Launches Public Offering Of Stock And Warrants - Nasdaq
Cabaletta Bio (CABA) Shares Drop 20% After Public Offering Annou - GuruFocus
Cabaletta Bio (CABA) Showcases Promising Rese-cel Data at EULAR 2025 | CABA Stock News - GuruFocus
Cabaletta Bio announces public offering of common stock and warrants By Investing.com - Investing.com South Africa
Cabaletta Bio prices $100 million public offering of shares and warrants By Investing.com - Investing.com South Africa
Cabaletta reports positive clinical data for autoimmune cell therapy By Investing.com - Investing.com South Africa
Cabaletta Bio looks to raise $100M in stock sale to fund cell therapy development - The Business Journals
Cabaletta Bio (CABA) Receives Reiterated Buy Rating from HC Wain - GuruFocus
Cabaletta Bio (CABA) Receives Reiterated Buy Rating from HC Wainwright & Co. | CABA Stock News - GuruFocus
Cabaletta Bio shares CAR-T results in three autoimmune conditions - Endpoints News
Cabaletta Bio Prices Securities Offering; Shares Fall - MarketScreener
Cabaletta Bio stock tumbles after pricing $100 million public offering By Investing.com - Investing.com Nigeria
Cabaletta Bio stock tumbles after pricing $100 million public offering - Investing.com Australia
Cabaletta Bio Announces Pricing of Public Offering of Securities - GuruFocus
Cabaletta Bio prices $100 million public offering of shares and warrants - Investing.com
Cabaletta Bio: Sector Headwinds And Funding Issues, But Also Some Clear Clinical Direction - Seeking Alpha
Cabaletta Bio announces public offering of common stock and warrants - Investing.com
Cabaletta Bio (CABA) Launches Public Offering with Warrants | CABA Stock News - GuruFocus
Cabaletta Bio Announces Proposed Public Offering of Securities | - GuruFocus
Cabaletta Bio Announces Proposed Public Offering of Securities - The Manila Times
Cabaletta Bio Announces Proposed Public Offering of Securities | CABA Stock News - GuruFocus
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in - GuruFocus
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress | CABA Stock News - GuruFocus
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress - The Manila Times
Cabaletta reports positive clinical data for autoimmune cell therapy - Investing.com
Breakthrough: New Autoimmune Therapy Achieves Drug-Free Remission in 94% of Trial Patients - Stock Titan
Cabaletta Bio Stockholders Approve Key Proposals - TipRanks
Cabaletta Bio Inc Azioni (CABA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):